Trial Profile
A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms COMETA-Breast
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 12 Jan 2023 Status changed from active, no longer recruiting to completed.
- 02 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.